Value of Surgical Treatment of Pulmonary Metastases in Multimodality Therapy

GU Li-jia,WU Yi-long,WENG Yi-min,FEN Wei-neng,CHENG Chao,ZHONG Wen-zhao,HUANG Shao-hong
DOI: https://doi.org/10.3969/j.issn.1005-8982.2005.06.048
2005-01-01
Abstract:To study the value of surgical treatment of pulmonary metastases in multimodality therapy. The clinical data and multimodality therapy effect of 27 patients of pulmonary metastases were analysed retrospectively. The pathological diagnosis of 27 pulmonary metastases were all alike to primary tumor.27 patients of pulmonary metastases were follow up, the follow-up rate is 100.0%. The 1-year and 3-year survival were 96.3% and 74.6% for the 27 patients. The median survival time was 38 months. The 1-year and 3-year survival were 75.0% and 31.3%, median survival time was 24 months, for the 8 patients of pulmonary metastases with brain metastases and bone metastases. 9 patients of pulmonary metastases have recurred after first metastatectomy, the 8 patients were underwent second resection and 1 patient was underwent third resection, the 1-year survival rate and 3-year survival rate were 88.9% and 77.8%, median survival time was 48 months. There was no serious complication and operative mortality. [Conclusion] surgical treatment can prolong the survival time effectively in the multimodality therapy of pulmonary metastases. The surgical treatment is not contraindication for multiple metastases, if other metastasis tumor could be treated effectively. surgical treatment can prolong effectively the survival time of recurrences patient after metastatectomy in the multimodality therapy.
What problem does this paper attempt to address?